Asia Pacific Pharmacovigilance and Drug Safety Software Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis
Description
The pharmacovigilance and drug safety software market in the Asia Pacific region was valued at approximately US$ 44.40 million in 2023, with projections indicating it will grow to US$ 68.66 million by 2031. This growth represents a compound annual growth rate (CAGR) of 5.6% from 2023 to 2031.
A significant driver of this market expansion is the integration of advanced technologies such as artificial intelligence (AI), machine learning (ML), and natural language processing (NLP). These technologies are revolutionizing the traditionally resource-intensive processes associated with pharmacovigilance, leading to more informed and efficient operations. Modern pharmacovigilance software platforms are increasingly equipped with sophisticated analytics and AI capabilities that enhance the identification of safety signals. By analyzing large datasets, these tools can uncover correlations and patterns that might be missed by conventional methods. Furthermore, AI-driven predictive analytics can anticipate potential safety issues, enabling companies to implement proactive measures.
Machine learning models are particularly useful in predicting adverse events related to drug use. For example, pharmacovigilance initiatives utilize ML to analyze extensive datasets, identifying patterns that may suggest risks of adverse drug reactions. These algorithms excel at processing unstructured data, such as social media content and patient records, to forecast safety concerns effectively.
Several key players in the market are developing automated AI-based monitoring tools to facilitate drug development for pharmaceutical companies. Notably, in May 2021, Clarivate introduced DialogML, an AI-driven pharmacovigilance literature monitoring software platform. This tool automates the monitoring of pharmacovigilance literature, streamlining processes such as aggregate report generation and safety signal reviews. In January 2024, PubHive Ltd. launched an innovative centralized summary of product characteristics (SmPC) management platform that incorporates AI-powered pharmacovigilance workflows. This platform is designed for life sciences, pharmaceutical companies, and clinical research organizations (CROs), enhancing compliance and operational efficiency for pharmacovigilance teams.
The use of AI systems is increasingly prevalent in real-time drug safety monitoring, which encompasses clinical trial data, medical literature reviews, and patient registries to identify adverse events (AEs). This proactive approach improves the accuracy and speed of adverse drug reaction (ADR) detection. Additionally, NLP technologies enable AI systems to extract pertinent information, such as drug names and symptoms, from extensive textual datasets, facilitating rapid and accurate adverse event reporting. This capability accelerates the identification of new or previously unknown drug safety issues, significantly advancing pharmacovigilance efforts.
The Asia Pacific pharmacovigilance and drug safety software market is segmented into various countries, including India, China, Japan, South Korea, Australia, and the rest of the Asia Pacific region. The region is experiencing a surge in digitization within its healthcare and pharmaceutical sectors. For instance, the Indian government has initiated several programs, such as the Ayushman Bharat Digital Mission and the CoWIN App, aimed at enhancing healthcare accessibility. Similarly, Australia has committed to modernizing its healthcare and pharmaceutical sectors, with a notable investment of US$ 74.91 thousand (AU$ 107.2 thousand) announced in March 2022.
The integration of AI in pharmacovigilance and drug safety software is becoming increasingly common among pharmaceutical companies, which utilize these systems to monitor, collect, analyze, and manage drug safety data. As the demand for pharmacovigilance grows across the region, there is a marked shift towards adopting advanced software solutions. These tools are employed throughout various stages of drug development, including pre-marketing and post-marketing surveillance, as well as during clinical trials. Consequently, the rise in digitalization initiatives within the pharmaceutical sector and the increasing adoption of pharmacovigilance software are expected to drive market growth in the Asia Pacific region.
The market is further categorized based on offerings, deployment methods, enterprise size, software form, functionality, and end users. In terms of offerings, the market is divided into software and services, with the software segment holding a larger share in 2023. Regarding deployment, the cloud segment has also captured a significant market share, reflecting a preference for cloud-based solutions.
When considering enterprise size, large enterprises dominate the market, while the software form is categorized into standard and customized solutions, with standard software leading in market share. Functionality-wise, the market includes segments such as signal and risk management, adverse event tracking, case management, and clinical safety management, with signal and risk management being the most prominent segment.
In terms of end users, pharmaceutical and biotechnology companies represent the largest segment, while the market is also segmented by country, with China leading in market share in 2023.
Key players in the Asia Pacific pharmacovigilance and drug safety software market include Veeva Systems Inc., IQVIA Holdings Inc., AB Cube S.A.S., ArisGlobal LLC, Oracle Corp, Max Application, ICON Plc, Cognizant Technology Solutions Corp, Accenture Plc, Syneos Health Inc., Genpact Ltd., Laboratory Corp of America Holdings, Parexel International Corp, Qinecsa Solutions, and Clinevo Technologies. These companies are at the forefront of developing innovative solutions that enhance drug safety and pharmacovigilance practices.
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific pharmacovigilance and drug safety software market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pharmacovigilance and drug safety software market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the pharmacovigilance and drug safety software market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
A significant driver of this market expansion is the integration of advanced technologies such as artificial intelligence (AI), machine learning (ML), and natural language processing (NLP). These technologies are revolutionizing the traditionally resource-intensive processes associated with pharmacovigilance, leading to more informed and efficient operations. Modern pharmacovigilance software platforms are increasingly equipped with sophisticated analytics and AI capabilities that enhance the identification of safety signals. By analyzing large datasets, these tools can uncover correlations and patterns that might be missed by conventional methods. Furthermore, AI-driven predictive analytics can anticipate potential safety issues, enabling companies to implement proactive measures.
Machine learning models are particularly useful in predicting adverse events related to drug use. For example, pharmacovigilance initiatives utilize ML to analyze extensive datasets, identifying patterns that may suggest risks of adverse drug reactions. These algorithms excel at processing unstructured data, such as social media content and patient records, to forecast safety concerns effectively.
Several key players in the market are developing automated AI-based monitoring tools to facilitate drug development for pharmaceutical companies. Notably, in May 2021, Clarivate introduced DialogML, an AI-driven pharmacovigilance literature monitoring software platform. This tool automates the monitoring of pharmacovigilance literature, streamlining processes such as aggregate report generation and safety signal reviews. In January 2024, PubHive Ltd. launched an innovative centralized summary of product characteristics (SmPC) management platform that incorporates AI-powered pharmacovigilance workflows. This platform is designed for life sciences, pharmaceutical companies, and clinical research organizations (CROs), enhancing compliance and operational efficiency for pharmacovigilance teams.
The use of AI systems is increasingly prevalent in real-time drug safety monitoring, which encompasses clinical trial data, medical literature reviews, and patient registries to identify adverse events (AEs). This proactive approach improves the accuracy and speed of adverse drug reaction (ADR) detection. Additionally, NLP technologies enable AI systems to extract pertinent information, such as drug names and symptoms, from extensive textual datasets, facilitating rapid and accurate adverse event reporting. This capability accelerates the identification of new or previously unknown drug safety issues, significantly advancing pharmacovigilance efforts.
The Asia Pacific pharmacovigilance and drug safety software market is segmented into various countries, including India, China, Japan, South Korea, Australia, and the rest of the Asia Pacific region. The region is experiencing a surge in digitization within its healthcare and pharmaceutical sectors. For instance, the Indian government has initiated several programs, such as the Ayushman Bharat Digital Mission and the CoWIN App, aimed at enhancing healthcare accessibility. Similarly, Australia has committed to modernizing its healthcare and pharmaceutical sectors, with a notable investment of US$ 74.91 thousand (AU$ 107.2 thousand) announced in March 2022.
The integration of AI in pharmacovigilance and drug safety software is becoming increasingly common among pharmaceutical companies, which utilize these systems to monitor, collect, analyze, and manage drug safety data. As the demand for pharmacovigilance grows across the region, there is a marked shift towards adopting advanced software solutions. These tools are employed throughout various stages of drug development, including pre-marketing and post-marketing surveillance, as well as during clinical trials. Consequently, the rise in digitalization initiatives within the pharmaceutical sector and the increasing adoption of pharmacovigilance software are expected to drive market growth in the Asia Pacific region.
The market is further categorized based on offerings, deployment methods, enterprise size, software form, functionality, and end users. In terms of offerings, the market is divided into software and services, with the software segment holding a larger share in 2023. Regarding deployment, the cloud segment has also captured a significant market share, reflecting a preference for cloud-based solutions.
When considering enterprise size, large enterprises dominate the market, while the software form is categorized into standard and customized solutions, with standard software leading in market share. Functionality-wise, the market includes segments such as signal and risk management, adverse event tracking, case management, and clinical safety management, with signal and risk management being the most prominent segment.
In terms of end users, pharmaceutical and biotechnology companies represent the largest segment, while the market is also segmented by country, with China leading in market share in 2023.
Key players in the Asia Pacific pharmacovigilance and drug safety software market include Veeva Systems Inc., IQVIA Holdings Inc., AB Cube S.A.S., ArisGlobal LLC, Oracle Corp, Max Application, ICON Plc, Cognizant Technology Solutions Corp, Accenture Plc, Syneos Health Inc., Genpact Ltd., Laboratory Corp of America Holdings, Parexel International Corp, Qinecsa Solutions, and Clinevo Technologies. These companies are at the forefront of developing innovative solutions that enhance drug safety and pharmacovigilance practices.
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific pharmacovigilance and drug safety software market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pharmacovigilance and drug safety software market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the pharmacovigilance and drug safety software market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
Table of Contents
227 Pages
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 2.2 Market Attractiveness
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:
- 3.3 Assumptions and Limitations
- 4. Asia Pacific Pharmacovigilance and Drug Safety Software Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.3 Lit of Vendors in the Value Chain
- 5. Asia Pacific Pharmacovigilance and Drug Safety Software Market – Key Market Dynamics
- 5.1 Market Drivers
- 5.2 Market Restraints
- 5.3 Market Opportunities
- 5.4 Future Trends
- 5.5 Impact of Drivers and Restraints:
- 6. Asia Pacific Pharmacovigilance and Drug Safety Software Market – Analysis
- 6.1 Asia Pacific Pharmacovigilance and Drug Safety Software Market Revenue (US$ Thousand), 2021–2031
- 6.2 Asia Pacific Pharmacovigilance and Drug Safety Software Market Forecast Analysis
- 7. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis – by Offering
- 7.1 Software
- 7.1.1 Overview
- 7.1.2 Software: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 7.2 Services
- 7.2.1 Overview
- 7.2.2 Services: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 8. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis – by Deployment
- 8.1 Cloud
- 8.1.1 Overview
- 8.1.2 Cloud: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 8.2 On Premises
- 8.2.1 Overview
- 8.2.2 On Premises: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 9. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis – by Enterprise Size
- 9.1 Large Enterprises
- 9.1.1 Overview
- 9.1.2 Large Enterprises: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 9.2 SMEs
- 9.2.1 Overview
- 9.2.2 SMEs: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 10. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis – by Form
- 10.1 Standard
- 10.1.1 Overview
- 10.1.2 Standard: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 10.2 Customized
- 10.2.1 Overview
- 10.2.2 Customized: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 11. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis – by Functionality
- 11.1 Signal and Risk Management
- 11.1.1 Overview
- 11.1.2 Signal and Risk Management: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 11.2 Issue Tracking and Adverse Event Tracking
- 11.2.1 Overview
- 11.2.2 Issue Tracking and Adverse Event Tracking: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 11.3 Case Management
- 11.3.1 Overview
- 11.3.2 Case Management: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 11.4 Clinical Safety Management and Clinical Trial Safety
- 11.4.1 Overview
- 11.4.2 Clinical Safety Management and Clinical Trial Safety: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 11.5 Quality and Compliance
- 11.5.1 Overview
- 11.5.2 Quality and Compliance: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 11.6 Medical Writing
- 11.6.1 Overview
- 11.6.2 Medical Writing: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 11.7 Audit Support and Training Compliance
- 11.7.1 Overview
- 11.7.2 Audit Support and Training Compliance: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 11.8 Healthcare Analytics
- 11.8.1 Overview
- 11.8.2 Healthcare Analytics: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 11.9 Others
- 11.9.1 Overview
- 11.9.2 Others: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 12. Asia Pacific Pharmacovigilance and Drug Safety Software Market Analysis – by End User
- 12.1 Pharmaceutical and Biotechnology Companies
- 12.1.1 Overview
- 12.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 12.2 Contract Research Organizations
- 12.2.1 Overview
- 12.2.2 Contract Research Organizations: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 12.3 Business Process Outsourcing (BPO) Firms
- 12.3.1 Overview
- 12.3.2 Business Process Outsourcing (BPO) Firms: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 12.4 Others
- 12.4.1 Overview
- 12.4.2 Others: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 13. Asia Pacific Pharmacovigilance and Drug Safety Software Market – Country Analysis
- 13.1 Asia Pacific
- 13.1.1 Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country
- 13.1.1.1 Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country
- 13.1.1.2 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 13.1.1.2.1 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Offering
- 13.1.1.2.2 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Deployment
- 13.1.1.2.3 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Enterprise Size
- 13.1.1.2.4 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Form
- 13.1.1.2.5 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Functionality
- 13.1.1.2.6 China: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by End User
- 13.1.1.3 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 13.1.1.3.1 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Offering
- 13.1.1.3.2 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Deployment
- 13.1.1.3.3 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Enterprise Size
- 13.1.1.3.4 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Form
- 13.1.1.3.5 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Functionality
- 13.1.1.3.6 Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by End User
- 13.1.1.4 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 13.1.1.4.1 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Offering
- 13.1.1.4.2 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Deployment
- 13.1.1.4.3 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Enterprise Size
- 13.1.1.4.4 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Form
- 13.1.1.4.5 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Functionality
- 13.1.1.4.6 India: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by End User
- 13.1.1.5 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 13.1.1.5.1 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Offering
- 13.1.1.5.2 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Deployment
- 13.1.1.5.3 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Enterprise Size
- 13.1.1.5.4 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Form
- 13.1.1.5.5 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Functionality
- 13.1.1.5.6 South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by End User
- 13.1.1.6 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 13.1.1.6.1 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Offering
- 13.1.1.6.2 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Deployment
- 13.1.1.6.3 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Enterprise Size
- 13.1.1.6.4 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Form
- 13.1.1.6.5 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Functionality
- 13.1.1.6.6 Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by End User
- 13.1.1.7 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- 13.1.1.7.1 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Offering
- 13.1.1.7.2 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Deployment
- 13.1.1.7.3 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Enterprise Size
- 13.1.1.7.4 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Form
- 13.1.1.7.5 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by Functionality
- 13.1.1.7.6 Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market Share – by End User
- 14. Competitive Landscape
- 14.1 Heat Map Analysis by Key Players
- 14.2 Company Positioning and Concentration
- 15. Industry Landscape
- 15.1 Overview
- 15.2 Market Initiative
- 15.3 Partnerships and Collaborations
- 16. Company Profiles
- 16.1 ArisGlobal LLC
- 16.1.1 Key Facts
- 16.1.2 Business Description
- 16.1.3 Products and Services
- 16.1.4 Financial Overview
- 16.1.5 SWOT Analysis
- 16.1.6 Key Developments
- 16.2 Max Application
- 16.2.1 Key Facts
- 16.2.2 Business Description
- 16.2.3 Products and Services
- 16.2.4 Financial Overview
- 16.2.5 SWOT Analysis
- 16.2.6 Key Developments
- 16.3 Oracle Corp
- 16.3.1 Key Facts
- 16.3.2 Business Description
- 16.3.3 Products and Services
- 16.3.4 Financial Overview
- 16.3.5 SWOT Analysis
- 16.3.6 Key Developments
- 16.4 Veeva Systems Inc
- 16.4.1 Key Facts
- 16.4.2 Business Description
- 16.4.3 Products and Services
- 16.4.4 Financial Overview
- 16.4.5 SWOT Analysis
- 16.4.6 Key Developments
- 16.5 IQVIA Holdings Inc
- 16.5.1 Key Facts
- 16.5.2 Business Description
- 16.5.3 Products and Services
- 16.5.4 Financial Overview
- 16.5.5 SWOT Analysis
- 16.5.6 Key Developments
- 16.6 ICON Plc
- 16.6.1 Key Facts
- 16.6.2 Business Description
- 16.6.3 Products and Services
- 16.6.4 Financial Overview
- 16.6.5 SWOT Analysis
- 16.6.6 Key Developments
- 16.7 Cognizant Technology Solutions Corp
- 16.7.1 Key Facts
- 16.7.2 Business Description
- 16.7.3 Products and Services
- 16.7.4 Financial Overview
- 16.7.5 SWOT Analysis
- 16.7.6 Key Developments
- 16.8 Accenture Plc
- 16.8.1 Key Facts
- 16.8.2 Business Description
- 16.8.3 Products and Services
- 16.8.4 Financial Overview
- 16.8.5 SWOT Analysis
- 16.8.6 Key Developments
- 16.9 Syneos Health Inc
- 16.9.1 Key Facts
- 16.9.2 Business Description
- 16.9.3 Products and Services
- 16.9.4 Financial Overview
- 16.9.5 SWOT Analysis
- 16.9.6 Key Developments
- 16.10 Genpact Ltd.
- 16.10.1 Key Facts
- 16.10.2 Business Description
- 16.10.3 Products and Services
- 16.10.4 Financial Overview
- 16.10.5 SWOT Analysis
- 16.10.6 Key Developments
- 16.11 AB Cube S.A.S.
- 16.11.1 Key Facts
- 16.11.2 Business Description
- 16.11.3 Products and Services
- 16.11.4 Financial Overview
- 16.11.5 SWOT Analysis
- 16.11.6 Key Developments
- 16.12 Laboratory Corp of America Holdings
- 16.12.1 Key Facts
- 16.12.2 Business Description
- 16.12.3 Products and Services
- 16.12.4 Financial Overview
- 16.12.5 SWOT Analysis
- 16.12.6 Key Developments
- 16.13 Parexel International Corp
- 16.13.1 Key Facts
- 16.13.2 Business Description
- 16.13.3 Products and Services
- 16.13.4 Financial Overview
- 16.13.5 SWOT Analysis
- 16.13.6 Key Developments
- 16.14 Qinecsa Solutions
- 16.14.1 Key Facts
- 16.14.2 Business Description
- 16.14.3 Products and Services
- 16.14.4 Financial Overview
- 16.14.5 SWOT Analysis
- 16.14.6 Key Developments
- 16.15 Clinevo Technologies
- 16.15.1 Key Facts
- 16.15.2 Business Description
- 16.15.3 Products and Services
- 16.15.4 Financial Overview
- 16.15.5 SWOT Analysis
- 16.15.6 Key Developments
- 17. Appendix
- 17.1 About Us
- 17.2 List of Abbreviations
- LIST OF TABLES
- Table 1. Asia Pacific Pharmacovigilance and Drug Safety Software Market Segmentation
- Table 2. List of Vendors
- Table 3. Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand)
- Table 4. Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand) – by Offering
- Table 5. Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand) – by Deployment
- Table 6. Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand) – by Enterprise Size
- Table 7. Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand) – by Form
- Table 8. Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand) – by Functionality
- Table 9. Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand) – by End User
- Table 10. Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021–2031 (US$ Thousand) – by Country
- Table 11. China: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Offering
- Table 12. China: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Deployment
- Table 13. China: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Enterprise Size
- Table 14. China: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Form
- Table 15. China: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Functionality
- Table 16. China: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by End User
- Table 17. Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Offering
- Table 18. Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Deployment
- Table 19. Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Enterprise Size
- Table 20. Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Form
- Table 21. Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Functionality
- Table 22. Japan: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by End User
- Table 23. India: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Offering
- Table 24. India: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Deployment
- Table 25. India: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Enterprise Size
- Table 26. India: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Form
- Table 27. India: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Functionality
- Table 28. India: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by End User
- Table 29. South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Offering
- Table 30. South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Deployment
- Table 31. South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Enterprise Size
- Table 32. South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Form
- Table 33. South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Functionality
- Table 34. South Korea: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by End User
- Table 35. Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Offering
- Table 36. Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Deployment
- Table 37. Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Enterprise Size
- Table 38. Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Form
- Table 39. Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Functionality
- Table 40. Australia: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by End User
- Table 41. Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Offering
- Table 42. Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Deployment
- Table 43. Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Enterprise Size
- Table 44. Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Form
- Table 45. Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by Functionality
- Table 46. Rest of APAC: Asia Pacific Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast, 2021 – 2031 (US$ Thousand) – by End User
- Table 47. List of Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
